C-A1SW3D tissue models, multi-omics, drug discovery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Develop tryptanthrin derivative compounds and uses for those compounds.
Patent family covering tryptanthrin derivatives, salts, and substituted heterocyclic compounds assigned to Viscient Bio Inc.
Patent applications in the family include CA3250182A1 published 2023-11-02 and AR129148A1 published 2024-07-24, with priority date 2022-04-26.
Discover disease drivers and develop drugs using human-relevant disease models.
Three-dimensional disease models made from human cells combined with multi-omics analysis, including genomics, transcriptomics, and metabolomics.
Platform is described as Viscient's core approach for drug discovery and development.
The site states Viscient's liver model was declared to contain all characteristics of fatty liver disease by Dr. David Brenner.
Model nonalcoholic steatohepatitis in a fully human system to identify clinically active targets and therapies.
Three-dimensional bioprinted liver tissue using primary human hepatocytes and nonparenchymal liver cells, including hepatic stellate cells, liver sinusoidal endothelial cells, and Kupffer cells, sourced from healthy or NASH donors.
Publication described a human primary cell 3D NASH model and examined the roles of hepatic stellate and liver sinusoidal endothelial cells.
Diseased-donor bioprinted tissues showed a NASH phenotype including fibrosis without added disease-inducing agents; chimeric tissues implicated hepatic stellate and liver sinusoidal endothelial cells in disease processes.
Improve understanding and prognostic characterization of NASH progression by analyzing liver cell morphology at single-cell resolution.
3D imaging flow cytometry with transmission and side-scattered images, 3D digital reconstructions, morphometric and texture parameters, and an autoencoder convolutional neural network for classification.
Scientific Reports publication reported use of 3D imaging flow cytometry and AI to characterize hepatic stellate cells and liver endothelial cells from NASH subjects and healthy controls.
The study reported regulated cell types involved in NASH development and classification performance superior to conventional machine learning methods.
Develop a drug for non-alcoholic steatohepatitis/fatty liver disease using Viscient's human 3D tissue and multi-omics discovery approach.
Drug discovery and development based on three-dimensional disease models made from human cells, with genomics, transcriptomics, metabolomics, and related multi-omics analysis.
The site states Viscient has advanced one drug to the preclinical level while preparing it for Phase 1 studies.